ANTHRACYCLINES ROLE IN ADJUVANT TREATMENT OF BREAST CANCER

€10.00
Tax included
Quantity
Add to wishlist
In Stock

Anthracyclines are used in the adjuvant treatment of breast cancer for about 25 years. Recently in the light of new data on taxanes and targeted therapies (trastuzumab) that have proven their effectiveness and the emergence of new predictors of sensitivity to anthracyclines, it was asked the following questions:
1. Is it possible to dispense with anthracyclines and taxanes for the benefit of targeted therapies?!
2. Should we prescribe to all patients anthracyclines?!
3. Is there any predictive factors for selecting patients who will benefit most from anthracyclines.
SKU-1109
30 Items
2050-01-01
New

16 other products in the same category:

Availability: 30 In Stock

While one wonders about the business of the twenty-first century and "the company post-crisis", it is useful to return to the original company of the twentieth century. Under what conditions it is born? What explains the forms that we know? And what are the foundations that could now be challenged? Berle and Means provide a historical interest, since their book The Modern Corporation and Private porperty (1932) analyzes the emergence of modern business in the early the twentieth century.

This website uses cookies to ensure you get the best experience on our website